Sprionolactone for Adult Female Acne (SAFA): pragmatic multi-centre double-blind randomised superiority trial to investigate the clinical and cost-effectiveness of sprionolactone for moderate or severe persistent acne in women

Sach, Tracey (Principal Investigator)
Sach, Tracey (CTU Role)

Status	Finished
Effective start/end date	1/04/18 → 31/08/22

Funding

National Institute for Health and Care Research: £65,532.00

1 Article

Clinical and cost-effectiveness of spironolactone in treating persistent facial acne in women: SAFA double-blinded RCT
Santer, M., Lawrence, M., Pyne, S., Renz, S., Stuart, B., Sach, T., Ridd, M., Thomas, K., Nuttall, J., Permyakova, N., Eminton, Z., Francis, N., Little, P., Muller, I., Soulsby, I., Thomas, K., Griffiths, G. & Layton, A. M., Sep 2024, In: Health Technology Assessment. 28, 56
Research output: Contribution to journal › Article › peer-review

Open Access
File